Carlsmed (NASDAQ:CARL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Carlsmed (NASDAQ:CARL) from a sell rating to a hold rating in a research note released on Saturday.

Other research analysts have also issued research reports about the company. Weiss Ratings reiterated a “sell (e-)” rating on shares of Carlsmed in a research report on Monday, December 22nd. The Goldman Sachs Group restated a “buy” rating and set a $20.00 price objective on shares of Carlsmed in a research report on Friday, January 9th. Truist Financial reiterated a “buy” rating and issued a $20.00 target price (up previously from $18.00) on shares of Carlsmed in a report on Friday, November 7th. Finally, BTIG Research restated a “buy” rating and set a $24.00 price target on shares of Carlsmed in a report on Monday, December 15th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Carlsmed currently has a consensus rating of “Moderate Buy” and an average price target of $21.33.

Carlsmed Stock Up 1.8%

CARL stock opened at $10.95 on Friday. Carlsmed has a 52 week low of $10.65 and a 52 week high of $17.19. The company has a market capitalization of $291.16 million and a price-to-earnings ratio of -3.28. The company’s fifty day simple moving average is $12.66. The company has a quick ratio of 11.91, a current ratio of 12.03 and a debt-to-equity ratio of 0.14.

Institutional Investors Weigh In On Carlsmed

Several hedge funds and other institutional investors have recently modified their holdings of CARL. Janney Montgomery Scott LLC boosted its holdings in Carlsmed by 6.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 15,800 shares of the company’s stock valued at $195,000 after acquiring an additional 1,000 shares during the period. Barclays PLC lifted its position in shares of Carlsmed by 10.6% during the fourth quarter. Barclays PLC now owns 10,633 shares of the company’s stock worth $131,000 after purchasing an additional 1,021 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Carlsmed during the third quarter valued at $33,000. JPMorgan Chase & Co. bought a new position in shares of Carlsmed in the third quarter worth about $37,000. Finally, Wells Fargo & Company MN increased its stake in Carlsmed by 61.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock worth $97,000 after buying an additional 2,989 shares during the period.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).